CRL

The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

Retrieved on: 
Tuesday, April 30, 2024
Class Action Lawsuit, Professional Services, Legal, Suite, FDA, Law, CRL, News, Symantec Endpoint Protection

The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN ) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN ) on behalf of investors concerning the Company’s possible violations of federal securities laws.
  • On April 8, 2024, Supernus announced that the FDA had issued a Complete Response Letter (“CRL”) in response to the Company’s New Drug Application for its Parkinson’s disease treatment, SPN-830.
  • On this news, Supernus’s stock price fell $2.12, or 6.3%, to close at $31.43 per share on April 8, 2024, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

Retrieved on: 
Tuesday, April 30, 2024
Professional Services, Class Action Lawsuit, Suite, FDA, Law, CRL, CMC, News, Symantec Endpoint Protection

The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO ) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO ) on behalf of investors concerning the Company’s possible violations of federal securities laws.
  • If you are a shareholder who suffered a loss, click here to participate.
  • If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally

Retrieved on: 
Monday, April 22, 2024
Environmental, Social and Governance (ESG), Alternative Energy, Green Technology, Energy, Climate Change, Sustainability, Socially Responsible Investing, Pharmaceutical, General Health, Professional Services, Medical Devices, Environment, Biotechnology, Science, Research, Health, RE100, Privacy law, Schneider Electric, Heat, Partnership, Electricity, Urban Saints, Repsol, Earth Day, GHG, Multimedia, CRL, Organization, Renewable resource, Corporate social responsibility, Renewable energy

In 2020, Charles River became one of the first 300 members of RE100 , a global corporate renewable energy initiative, and committed to operating on 100 percent renewable electricity globally by 2030.

Key Points: 
  • In 2020, Charles River became one of the first 300 members of RE100 , a global corporate renewable energy initiative, and committed to operating on 100 percent renewable electricity globally by 2030.
  • View the full release here: https://www.businesswire.com/news/home/20240422679591/en/
    In efforts to reach its renewable electricity target, Charles River has:
    Executed two critical virtual power purchase agreements (vPPAs) in the United States and Europe.
  • In 2022, Charles River was recognized by the U.S. Environmental Protection Agency’s Green Power Partnership as a leader in green electricity use.
  • Charles River also sponsored Energize , a program powered by Schneider Electric to increase access to renewable energy for pharmaceutical supply chains.

Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing

Retrieved on: 
Tuesday, April 16, 2024
Research, Animal Welfare, Medical Devices, Public Policy, Government, Biotechnology, Health, Pharmaceutical, General Health, Science, Corporation, Safety, Policy, Valo, AI, Animal, Pathology, Logica, Patient safety, AMAP, Patient, The three Rs, Multimedia, Non-governmental organization, Drug development, CRL, Drug discovery, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.
  • This investment spans a portfolio of technology innovations, partnerships, and advocacy efforts to reduce the use of animal testing.
  • View the full release here: https://www.businesswire.com/news/home/20240416134140/en/
    Understanding that stakeholders across drug development must collaborate to pursue these advances, AMAP is comprised of Charles River experts in animal welfare, science, technology, operations, and advocacy.
  • AMAP focus is on three key pillars:
    Products & Services: Charles River is committed to innovating and expanding its portfolio to include more animal alternatives.

Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call

Retrieved on: 
Friday, April 12, 2024
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, CRL

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens.
  • A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m.
  • Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com .
  • A replay will be accessible through the same website.

Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology

Retrieved on: 
Thursday, April 11, 2024
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Medical Devices, Research, Software, Artificial Intelligence, Science, Safety, Tissue, Doctor of Philosophy, Pathology, Marie Cassidy, Charles River Laboratories, MBA, Drug development, CRL, Drug discovery, WSI, Organization

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.
  • In experimental and toxicologic pathology in particular, traditional light microscopic pathology methods can fall short of maintaining consistency and efficiency in analyzing histopathology data.
  • By augmenting evaluations with decision support technology, toxicologic pathologists have access to simple, visual tools to facilitate efficiency, consistency, and accuracy in their work.
  • Developed through a research collaboration between Charles River and Deciphex, Patholytix Foresight incorporates organ-based lesion classifiers created from an extensive data warehouse.

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, April 10, 2024
FDA, Radiation, CMO, News, Complaint, Patient, Court, BLA, CRL, Person, Insurance

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Key Points: 
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660 .
  • If you suffered a loss in Checkpoint you have until June 4, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, April 9, 2024
Radiation, CKPT, Patient, CRL, News, Complaint, CMO, FDA, BLA, Court, Person

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Key Points: 
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Checkpoint you have until June 4, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Checkpoint Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 9, 2024
Radiation, CKPT, Biologics license application, Telephone, District court, Patient, CRL, News, Acquisition, Complaint, P.C, CMO, FDA, BLA, Court, Food, Person, Pharmaceutical industry

Investors have until June 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until June 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Checkpoint's lead antibody product candidate is cosibelimab for the treatment of selected recurrent or metastatic cancers.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO] as approvability issues to address in a resubmission."

Supernus Provides Regulatory Update for SPN-830

Retrieved on: 
Monday, April 8, 2024
Symantec Endpoint Protection, PD, Central nervous system, Patient, CNS, Food and Drug Administration, CRL, NDA, FDA, Food

ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830.

Key Points: 
  • ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830.
  • The FDA has issued a Complete Response Letter (CRL) in response to the Company’s New Drug Application (NDA) for SPN-830.
  • The CRL mentions two areas that require additional review by the FDA or additional information to be provided to the FDA.
  • We will work with the FDA to address the CRL and to successfully resubmit our SPN-830 NDA,” said Jack Khattar, President & CEO of Supernus.